Study provides new insights on how diabetes drug works

February 10, 2017

Many individuals with type 2 diabetes produce abnormally low levels of a gut hormone called GLP-1, which normally stimulates insulin release from the pancreas.

Now a new study shows that GLP-1 production by special cells in the gut known as L-cells can be restored in patients with recent onset type 2 diabetes following three to 12 months of treatment with liraglutide, a drug that is similar to native GLP-1.

"This study shows that chronic liraglutide therapy induces a robust enhancement of GLP-1 secretion by the body that may hold implications for the of this medication in patients," said Dr. Ravi Retnakaran, senior author of the Diabetes, Obesity and Metabolism study.

Explore further: Liraglutide doesn't affect gastric emptying in type 1 diabetes

More information: Thomas Forst et al, Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study, Diabetes, Obesity and Metabolism (2017). DOI: 10.1111/dom.12838

Related Stories

Liraglutide doesn't affect gastric emptying in type 1 diabetes

November 28, 2016
(HealthDay)—For individuals with type 1 diabetes mellitus (T1DM), liraglutide therapy does not affect the rate of gastric emptying (GE) during hypoglycemia, according to a study published online Nov. 21 in Diabetes, Obesity ...

Type 2 diabetes drug can exhaust insulin-producing cells

February 11, 2016
Long-term use of liraglutide, a substance that helps to lower blood sugar levels in patients with type 2 diabetes, can have a deteriorating effect on insulin-producing beta cells, leading to an increase in blood sugar levels. ...

Drug helps patients with diabetes lose weight

August 18, 2015
Among overweight and obese patients with type 2 diabetes, daily injection of the diabetes drug liraglutide with a modified insulin pen device, in addition to diet and exercise, resulted in greater weight loss over 56 weeks ...

Liraglutide, sitagliptin have no effect on renal hemodynamics

September 9, 2016
(HealthDay)—In insulin-naive patients with type 2 diabetes, 12 weeks of treatment with liraglutide or sitagliptin has no effect on renal hemodynamics, according to a study published online Sept. 1 in Diabetes Care.

Liraglutide tops lixisenatide as add-on to metformin in T2DM

June 28, 2016
(HealthDay)—For patients with type 2 diabetes taking metformin, add-on liraglutide is more effective than lixisenatide for improving glycemic control, according to a study published online June 16 in Diabetes Care.

Protein packaging may cause the immune attacks of type 1 diabetes

November 21, 2016
Type-1 diabetes occurs when immune cells attack the pancreas. EPFL scientists have now discovered what may trigger this attack, opening new directions for treatments.

Recommended for you

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Omega-6 fats may help prevent type 2 diabetes

October 11, 2017
The risk of developing type 2 diabetes could be significantly reduced by eating a diet rich in omega-6 polyunsaturated fats, a new study suggests.

Where there's type 1 diabetes, celiac disease may follow

October 10, 2017
(HealthDay)—Parents of young children with type 1 diabetes need to be on the lookout for symptoms of another autoimmune condition—celiac disease, new research suggests.

Type 1 diabetes and the microbiota—MAIT cells as biomarkers and new therapeutic targets

October 10, 2017
Together with colleagues from AP-HP Necker–Enfants Malades Hospital in Paris, scientists from the Cochin Institute (CNRS / INSERM / Paris Descartes University) have discovered that the onset of type 1 diabetes is preceded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.